ITEM 1.01 Entry into a Material Definitive Agreement.
On December 19, 2022, ITI Limited, a wholly-owned subsidiary of Intra-Cellular
Therapies, Inc. (the "Company"), entered into Amendment No. 1 (the "Amendment")
to the Master Services Agreement dated as of January 10, 2017 (the "MSA") by and
between Lonza Ltd ("Lonza") and ITI Limited, to, among other items, extend the
current term of the MSA until December 31, 2028 and provide for certain minimum
annual purchase commitments by the Company for the years 2025 through 2028 for
Lonza's manufacture of CAPLYTA.
The foregoing summary of the Amendment does not purport to be complete and is
qualified in its entirety by reference to the Amendment, a copy of which will be
attached as an exhibit to the Company's Annual Report on Form 10-K for the year
ending December 31, 2022.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses